Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma
NCT03943901Phase 2Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine sulfate liposome injection, prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Wisconsin–Madison. Started Feb 2021; status: active, not recruiting.
02
Drugs
rituximabcyclophosphamidepegylated liposomal doxorubicinvincristine sulfate liposome injectionprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03943901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943901.